Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 10/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.58 |
| ▸ | QDPR | P09417 | 1/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31518094 | 0.87 | ABCB1 (0.47) | HTR1ASLC6A2SLC6A4SLC6A3CHRNB2 | |
| SCHEMBL1765128 | 0.87 | HTR1A (0.67) | HTR1ASLC6A2SLC6A4SLC6A3SLC18A3 | |
| Hydrochloric Acid SCHEMBL6075201 | 0.85 | HTR1A (0.65) | HTR1ASLC6A2SLC6A4SLC6A3SLC18A3 | |
| SCHEMBL31614201 | 0.83 | ABCB1 (0.45) | HTR1ASLC6A2SLC6A4SLC6A3CHRNB2 | |
| SCHEMBL23215227 | 0.79 | QDPR (0.43) | HTR1ASLC6A2SLC6A4SLC6A3QDPR | |
| SCHEMBL4706866 | 0.79 | HTR1A (0.58) | HTR1ASLC6A2SLC6A4SLC6A3CHRNB2 | |
| SCHEMBL30852165 | 0.79 | HTR1A (0.58) | HTR1ASLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL29768397 | 0.79 | QDPR (0.43) | HTR1ASLC6A2SLC6A4SLC6A3QDPR | |
| SCHEMBL3466215 | 0.79 | HTR1A (0.58) | HTR1ASLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL5020018 | 0.79 | QDPR (0.47) | HTR1ASLC6A2SLC6A4SLC6A3QDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2638040-A1 | RADIOLABELLED mGLuR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-18 | — | — | EP | disclosed |
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-05 | — | — | US | disclosed |
| WO-2012062752-A1 | RADIOLABELLED mGLuR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062752-A1 | RADIOLABELLED mGLuR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | GRM2, GRM3, GRM1 | HTR1A 702/4885SLC6A2 182/4885SLC6A4 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.